AUXILIARY DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME USING CORRECTIVE DIET OR FECAL MICROBIOTA TRANSPLANTATION Russian patent published in 2021 - IPC C12Q1/04 C12N1/20 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology and provides a diagnostic method that can be used to determine the probability of that a subject with irritable bowel syndrome (hereinafter – IBS) will respond to the treatment using a corrective diet for IBS or fecal microbiota transplantation (hereinafter – FMT). In particular, this method can be used to predict or determine the probability of a positive reaction of a subject with IBS to the treatment using a corrective diet for IBS or FMT, especially to determine the probability that a corrective diet or FMT can have a positive (i.e., beneficial) effect on the gastrointestinal tract of the subject, specifically the microbiota of the gastrointestinal tract, or other symptoms or complications of IBS (for example, to reduce their severity). The proposed method is based on the analysis of the relative content of some bacteria in samples from the gastrointestinal tract, for example, by analyzing nucleic acids. The proposed method includes determining in a test sample from the gastrointestinal tract of a subject with irritable bowel syndrome a number of bacteria of at least one taxonomic group selected from Acinetobacter junii, Bacteroides stercosis, Bacteroides zoogleoformans, Dorea spp., Eubacterium siraeum, Clostridium sp., Eubacterium halli, Bacteroides spp., Firmicutes, Veillonella spp., Helicobacter spp., Clostridia, Shigella spp., Escherichia spp., Bacteroides spp. and Prevotella spp., and comparing the number of the specified bacteria from the specified at least one taxonomic group with a reference value obtained from at least one sample from the gastrointestinal tract of at least one subject without symptoms of irritable bowel syndrome, or a threshold value set as a median number of the specified bacteria in at least one sample from the gastrointestinal tract of at least one subject who demonstrated a reaction to the specified treatment, and determining a difference in the number of the specified bacteria in the test sample compared to the reference value or to the specified median threshold value in a smaller or larger direction. The number of bacteria in taxonomic groups Acinetobacter junii, Bacteroides stercosis, Bacteroides zoogleoformans, Dorea spp., Eubacterium siraeum, Clostridium sp., Eubacterium halli, Bacteroides spp., Firmicutes, Veillonella spp., Helicobacter spp., Clostridia, Shigella spp., Escherichia spp., Bacteroides spp. and Prevotella spp., exceeding reference values or the median threshold value, or the number of bacteria in taxonomic groups Bacteroides spp., Firmicutes, Veillonella spp., Helicobacter spp., Clostridia, Shigella spp., Escherichia spp., less than reference values or the specified median threshold value for the specified bacteria, is an indicator that the subject will respond to a corrective diet for irritable bowel syndrome.

EFFECT: invention makes it possible to increase the efficiency of the treatment of irritable bowel syndrome.

24 cl, 22 dwg, 2 tbl, 2 ex